In addition, 10–15% of ccRCC tumors have inactivating mutations in either BRCA1-associated protein 1 (BAP1) or SET domain containing 2 (SETD2), a histone deubiquitinase and a histone methyltransferase respectively [12]. Here, BAP1 is linked to nonpapillary renal cell carcinoma.